Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Electron Transport Chain Complex II Sustains High Mitochondrial Membrane Potential in Hematopoietic Stem and Progenitor Cells

Claudia Morganti, PhD, Massimo Bonora, PhD, Kyoko Ito, Keisuke Ito, MD PhD

Blood (2019) 134 (Supplement_1): 1188.

https://doi.org/10.1182/blood-2019-125891

Published: 2019

Journal Articles

Physiologically Based Pharmacokinetic (PBPK) Modeling for Betrixaban and the Impact of P-Glycoprotein Inhibition on Betrixaban Pharmacokinetics

Janet M. Leeds, PhD, Alice Ke, Karen Rowland Yeo, John T Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2017) 130 (Supplement 1): 3663.

https://doi.org/10.1182/blood.V130.Suppl_1.3663.3663

Published: 2017

Journal Articles

Co-Loaded Reversal Agent and Chemotherapeutic Nanoerythrosomes to Overcome Cancer Multidrug Resistance

Shuang Ding, MSc, Baoan Chen, MDPhD, Haijun ZHang, MDPhD, Jie Yang

Blood (2017) 130 (Supplement 1): 4995.

https://doi.org/10.1182/blood.V130.Suppl_1.4995.4995

Published: 2017

Journal Articles

Inhibition of MDR1 Overcomes Brentuximab Vedotin Resistance in Hodgkin Lymphoma Cell Line Model and Is Synergistic with Brentuximab Vedotin in Mouse Xenograft Model

Robert W Chen, MD, Jessie Hou, MS, Indu Nair, Jun Wu, PhD, Tim Synold, Larry W. Kwak, MD, Steven T. Rosen, MD, Stephen J. Forman, MD, Susan Kane, PhD, Edward Newman, PharmD

Blood (2016) 128 (22): 752.

https://doi.org/10.1182/blood.V128.22.752.752

Published: 2016

Journal Articles

Novel DNA-Damaging Linker Payloads Are Active in Models of Acquired Resistance to Calicheamicin and Standard of Care

Jennifer Kahler, Maureen Dougher, Jia Lu, MS, Jane Xu, MS, Tasneem Kausar, PhD, Luanna Lemon, Wenyan Zhong, PhD, Judy Lucas, Matthew Sung, PhD, Puja Sapra, PhD

Blood (2016) 128 (22): 3522.

https://doi.org/10.1182/blood.V128.22.3522.3522

Published: 2016

Journal Articles

BRAF V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation

Yo-Ting Tsai, MS, Gerard Lozanski, MD, Amy M. Lehman, MAS, Ellen Sass, Erin K. Hertlein, PhD, Santosh Salunke, Ching-Shih Chen, PhD, Michael R. Grever, MD, John C. Byrd, MD, David M. Lucas, PhD

Blood (2015) 126 (23): 2477.

https://doi.org/10.1182/blood.V126.23.2477.2477

Published: 2015

Journal Articles

Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations

Jennifer E Amengual, MD, Maximilian Lombardo, Kelly M Zullo, Paul M. Johannet, BA, Sathyen A Prabhu, Gonzalez Yulissa, Luigi Scotto, PhD, Ying Wei, Jimmy Duong, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 3708.

https://doi.org/10.1182/blood.V126.23.3708.3708

Published: 2015

Journal Articles

Characteristics of "Older Old" Patients with Sickle Cell Anemia Who Survived for More Than 80 Years

Dianne Pulte, MD, Gaye Riddick-Burden, MSN, Samir K. Ballas, MD

Blood (2015) 126 (23): 4599.

https://doi.org/10.1182/blood.V126.23.4599.4599

Published: 2015

Journal Articles

Decreased Expression of Nucleophosmin/B23 Increases Drug Sensitivity of Adriamycin-Resistant Lymphoblastic Leukemia Molt-4 Cells through mdr-1 Regulation

Jianda Hu, MD, Lingyan Wang, Dr., Buyuan Chen, Dr., MinHui Lin, Dr., Yanqin Cao, Yingyu Chen, Dr., Xinji Chen, Dr., Tingbo Liu, PhD

Blood (2014) 124 (21): 5229.

https://doi.org/10.1182/blood.V124.21.5229.5229

Published: 2014

Journal Articles

Development and Characterization of Two Lymphoma Cell Lines Resistant to the Selective HDAC6 Inhibitor Ricolinostat (ACY-1215) As a Tool to Better Understand the Biology of HDACs on Lymphoma

Jennifer E Amengual, MD, Paul M. Johannet, BA, Kelly Zullo, MS, Maximilian Lombardo, MS, Owen A. O'Connor, MD PhD

Blood (2014) 124 (21): 1777.

https://doi.org/10.1182/blood.V124.21.1777.1777

Published: 2014

Journal Articles

Vincristine and Prednisolone Combination Reduces MDR1 and Microenvironment-Mediated Treatment Resistance In Acute Lymphoblastic Leukemia

Nan Jiang, Ph.D., Zhenhua Li, Ph.D., Grace Shimin Koh, B.Sc., Yi Lu, Ph.D., Shirley K.Y. Kham, Allen Eng Juh Yeoh, MD

Blood (2013) 122 (21): 2529.

https://doi.org/10.1182/blood.V122.21.2529.2529

Published: 2013

Journal Articles

Targeting BTK As a Treatment For Multiple Myeloma Stem Cells

Ye Yang, PhD, Zhimin Gu, PhD, Hongwei Xu, DDS, Junwei Huang, MD, Jie He, MD, Yi Tao, MD&PhD, Guido J. Tricot, M.D., Ph.D., Fenghuang Zhan, MD&PhD

Blood (2013) 122 (21): 271.

https://doi.org/10.1182/blood.V122.21.271.271

Published: 2013

Journal Articles

The Conserved Kxgffkr Motif of α-Integrin Cytoplasmic Tail Mediates Chemoresistance to Doxorubicin in T-Cell Leukemia.

Chi-Chao Liu, Pascal Leclair, Daniel He, Eva Yap, Chinten James Lim, PhD

Blood (2012) 120 (21): 2467.

https://doi.org/10.1182/blood.V120.21.2467.2467

Published: 2012

Journal Articles

Real-World Study of Dabigatran Etexilate for Thromboprophylaxis in Over 5000 Hip or Knee Replacement Patients: Favourable Safety Profile in Subgroups with Different BMI, Renal Function and Age

Nadia Rosencher, MD, Simon Frostick, MD, Martin Feuring, MD, Eva Kleine, Martina Brueckmann, MD, Andreas Clemens, MD, Charles Marc Samama, MD

Blood (2012) 120 (21): 1160.

https://doi.org/10.1182/blood.V120.21.1160.1160

Published: 2012

Journal Articles

Detection, Phenotype and Prognostic Significance of the Leukemic Stem Cell Side Population Ho342low in Acute Myeloid Leukemia.

Juana Serrano-Lopez, Josefina Serrano, Joaquín Sanchez-Garcia, Noemi Fernandez-Escalada, Maria del Carmen Martinez-Losada, Javier Casaño, Salvador Tabares, Antonio P. Torres Gomez, MD

Blood (2012) 120 (21): 2586.

https://doi.org/10.1182/blood.V120.21.2586.2586

Published: 2012

Journal Articles

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Elodie Lainey, Marie Sebert, Cyrielle Bouteloup, Carole Leroy, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, MD, Guido Kroemer, MD, PhD, Pierre Fenaux, MD, PhD, Simone Boehrer, MD, PhD

Blood (2011) 118 (21): 2564.

https://doi.org/10.1182/blood.V118.21.2564.2564

Published: 2011

Journal Articles

Inhibition of RARα2 or Its Downstream Signaling Pathways Decreases Drug Resistance in Myeloma

Guido J. Tricot, MD, PhD, Ye Yang, PhD, Fang Xiao, PhD, Maurizio Zangari, MD, Hongwei Xu, MD, MS, Fenghuang Zhan, MD, PhD

Blood (2011) 118 (21): 989.

https://doi.org/10.1182/blood.V118.21.989.989

Published: 2011

Journal Articles

Secondary Acute Myeloid Leukemia (AML), Including Therapy-Related AML, Associates with Worse Treatment Outcomes, Than De Novo AML Even After Hematopoietic Stem Cell Transplantation, and Its Unfavorable Behavior Does Not Associated with Functional Activity of p-Glycoprotein, MDR1

Boram Han, Ha Yeon Lee, Jun Ho Yi, Jun Ho Jang, Kihyun Kim, Hee Jin Kim, Sun-Hee Kim, Chul Won Jung, Dong Hwan (Dennis) Kim

Blood (2010) 116 (21): 2157.

https://doi.org/10.1182/blood.V116.21.2157.2157

Published: 2010

Journal Articles

Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs

Marie Sebert, Elodie Lainey, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, Pierre Fenaux, MD, PhD, Guido Kroemer, Simone Boehrer

Blood (2010) 116 (21): 2163.

https://doi.org/10.1182/blood.V116.21.2163.2163

Published: 2010

Journal Articles

Novel Photodepletion Strategy to Preserve and Expand Tregs While Eliminating CD4+ Effector T Cells From Patients with Chronic Graft-Versus-Host Disease

Jean-Philippe Bastien, MSc, Gorazd Krosl, Ph.D, Cynthia Therien, BSc, MSc, Marissa Rashkovan, B.Sc, Christian Scotto, Ph.D, Sandra Cohen, MD, David S. Allan, MD, MSc, Donna E. Hogge, MD, PhD, R. Maarten Egeler, MD, Claude Perreault, MD, Denis-Claude Roy, MD

Blood (2010) 116 (21): 353.

https://doi.org/10.1182/blood.V116.21.353.353

Published: 2010

NARROW

Electron Transport Chain Complex II Sustains High Mitochondrial Membrane Potential in Hematopoietic Stem and Progenitor Cells

Physiologically Based Pharmacokinetic (PBPK) Modeling for Betrixaban and the Impact of P-Glycoprotein Inhibition on Betrixaban Pharmacokinetics

Co-Loaded Reversal Agent and Chemotherapeutic Nanoerythrosomes to Overcome Cancer Multidrug Resistance

Inhibition of MDR1 Overcomes Brentuximab Vedotin Resistance in Hodgkin Lymphoma Cell Line Model and Is Synergistic with Brentuximab Vedotin in Mouse Xenograft Model

Novel DNA-Damaging Linker Payloads Are Active in Models of Acquired Resistance to Calicheamicin and Standard of Care

BRAF V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation

Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations

Characteristics of "Older Old" Patients with Sickle Cell Anemia Who Survived for More Than 80 Years

Decreased Expression of Nucleophosmin/B23 Increases Drug Sensitivity of Adriamycin-Resistant Lymphoblastic Leukemia Molt-4 Cells through mdr-1 Regulation

Development and Characterization of Two Lymphoma Cell Lines Resistant to the Selective HDAC6 Inhibitor Ricolinostat (ACY-1215) As a Tool to Better Understand the Biology of HDACs on Lymphoma

Vincristine and Prednisolone Combination Reduces MDR1 and Microenvironment-Mediated Treatment Resistance In Acute Lymphoblastic Leukemia

Targeting BTK As a Treatment For Multiple Myeloma Stem Cells

The Conserved Kxgffkr Motif of α-Integrin Cytoplasmic Tail Mediates Chemoresistance to Doxorubicin in T-Cell Leukemia.

Real-World Study of Dabigatran Etexilate for Thromboprophylaxis in Over 5000 Hip or Knee Replacement Patients: Favourable Safety Profile in Subgroups with Different BMI, Renal Function and Age

Detection, Phenotype and Prognostic Significance of the Leukemic Stem Cell Side Population Ho342low in Acute Myeloid Leukemia.

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Inhibition of RARα2 or Its Downstream Signaling Pathways Decreases Drug Resistance in Myeloma

Secondary Acute Myeloid Leukemia (AML), Including Therapy-Related AML, Associates with Worse Treatment Outcomes, Than De Novo AML Even After Hematopoietic Stem Cell Transplantation, and Its Unfavorable Behavior Does Not Associated with Functional Activity of p-Glycoprotein, MDR1

Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs

Novel Photodepletion Strategy to Preserve and Expand Tregs While Eliminating CD4+ Effector T Cells From Patients with Chronic Graft-Versus-Host Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only